With a four-year, $3.3 million grant from the National Institutes of Health (NIH), researchers from Case Western Reserve University will study whether certain brain proteins may play a role in the development of Alzheimer’s disease.
FDA Gives Nod to Gene Therapy for Hemophilia A
The FDA approved valoctocogene roxaparvovec (Roctavian) as the first gene therapy for the treatment of adults with severe hemophilia A, drug developer Biomarin announced on
June 30, 2023